1620 Investment Advisors Inc. Acquires 157 Shares of Johnson & Johnson (NYSE:JNJ)

1620 Investment Advisors Inc. increased its stake in Johnson & Johnson (NYSE:JNJGet Rating) by 6.6% during the second quarter, Holdings Channel.com reports. The institutional investor owned 2,544 shares of the company’s stock after buying an additional 157 shares during the period. 1620 Investment Advisors Inc.’s holdings in Johnson & Johnson were worth $452,000 as of its most recent filing with the SEC.

Other large investors have also added to or reduced their stakes in the company. RE Dickinson Investment Advisors LLC lifted its position in shares of Johnson & Johnson by 163.3% during the 1st quarter. RE Dickinson Investment Advisors LLC now owns 158 shares of the company’s stock valued at $28,000 after buying an additional 98 shares during the last quarter. Morton Brown Family Wealth LLC raised its stake in Johnson & Johnson by 78.0% in the 2nd quarter. Morton Brown Family Wealth LLC now owns 178 shares of the company’s stock valued at $32,000 after acquiring an additional 78 shares during the period. Advanced Research Investment Solutions LLC boosted its position in Johnson & Johnson by 200.0% during the first quarter. Advanced Research Investment Solutions LLC now owns 180 shares of the company’s stock worth $32,000 after purchasing an additional 120 shares during the period. Professional Financial Advisors LLC increased its stake in shares of Johnson & Johnson by 47.9% in the first quarter. Professional Financial Advisors LLC now owns 210 shares of the company’s stock worth $37,000 after purchasing an additional 68 shares in the last quarter. Finally, Goodman Advisory Group LLC bought a new stake in shares of Johnson & Johnson in the second quarter valued at approximately $39,000. Hedge funds and other institutional investors own 68.59% of the company’s stock.

Insider Buying and Selling

In other Johnson & Johnson news, EVP Kathryn E. Wengel sold 16,410 shares of Johnson & Johnson stock in a transaction that occurred on Wednesday, November 9th. The shares were sold at an average price of $173.42, for a total transaction of $2,845,822.20. Following the transaction, the executive vice president now directly owns 71,311 shares of the company’s stock, valued at $12,366,753.62. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. In other Johnson & Johnson news, EVP Kathryn E. Wengel sold 16,410 shares of the company’s stock in a transaction dated Wednesday, November 9th. The shares were sold at an average price of $173.42, for a total transaction of $2,845,822.20. Following the completion of the sale, the executive vice president now directly owns 71,311 shares in the company, valued at $12,366,753.62. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Also, VP Peter Fasolo sold 22,864 shares of Johnson & Johnson stock in a transaction dated Wednesday, October 19th. The stock was sold at an average price of $164.50, for a total value of $3,761,128.00. Following the completion of the transaction, the vice president now owns 114,676 shares in the company, valued at approximately $18,864,202. The disclosure for this sale can be found here. Insiders sold 118,795 shares of company stock worth $20,230,174 in the last quarter. 0.35% of the stock is owned by insiders.

Johnson & Johnson Trading Up 0.8 %

Shares of Johnson & Johnson stock opened at $176.20 on Friday. The company has a 50 day simple moving average of $167.84 and a two-hundred day simple moving average of $171.40. The firm has a market cap of $460.67 billion, a PE ratio of 24.54, a PEG ratio of 3.44 and a beta of 0.57. Johnson & Johnson has a 1 year low of $155.72 and a 1 year high of $186.69. The company has a debt-to-equity ratio of 0.37, a current ratio of 1.43 and a quick ratio of 1.18.

Johnson & Johnson (NYSE:JNJGet Rating) last announced its earnings results on Tuesday, October 18th. The company reported $2.55 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.49 by $0.06. Johnson & Johnson had a net margin of 19.95% and a return on equity of 35.37%. The company had revenue of $23.79 billion during the quarter, compared to analyst estimates of $23.44 billion. During the same period in the previous year, the business earned $2.60 earnings per share. The firm’s quarterly revenue was up 1.9% compared to the same quarter last year. Analysts expect that Johnson & Johnson will post 10.04 earnings per share for the current fiscal year.

Johnson & Johnson announced that its board has authorized a share repurchase plan on Wednesday, September 14th that authorizes the company to repurchase $5.00 billion in shares. This repurchase authorization authorizes the company to buy up to 1.2% of its shares through open market purchases. Shares repurchase plans are generally an indication that the company’s management believes its stock is undervalued.

Johnson & Johnson Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 6th. Investors of record on Tuesday, November 22nd will be issued a dividend of $1.13 per share. The ex-dividend date of this dividend is Monday, November 21st. This represents a $4.52 dividend on an annualized basis and a dividend yield of 2.57%. Johnson & Johnson’s dividend payout ratio is 62.95%.

Wall Street Analyst Weigh In

A number of research analysts recently weighed in on the stock. Credit Suisse Group assumed coverage on shares of Johnson & Johnson in a research note on Thursday. They issued a “neutral” rating and a $170.00 price objective for the company. Morgan Stanley decreased their price objective on Johnson & Johnson from $174.00 to $170.00 and set an “equal weight” rating on the stock in a research note on Wednesday, October 19th. Sanford C. Bernstein cut their target price on Johnson & Johnson from $194.00 to $190.00 in a research note on Wednesday, October 19th. Citigroup decreased their price target on Johnson & Johnson from $201.00 to $198.00 in a research report on Wednesday, October 5th. Finally, Bank of America reduced their price objective on shares of Johnson & Johnson from $185.00 to $178.00 and set a “neutral” rating for the company in a research note on Friday, October 14th. Seven investment analysts have rated the stock with a hold rating, four have issued a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $181.33.

About Johnson & Johnson

(Get Rating)

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide. The company's Consumer Health segment offers baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR.

Recommended Stories

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJGet Rating).

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.